Seladelpar Explained

Width:	250
Tradename:	Livdelzi
Dailymedid:	Seladelpar
Routes Of Administration:	By mouth
Atc Prefix:	None
Legal Us:	Rx-only
Legal Us Comment:	^[1]
Cas Number:	851528-79-5
Pubchem:	11236126
Drugbank:	DB12390
Chemspiderid:	9411171
Unii:	7C00L34NB9
Kegg:	D11256
Chembl:	230158
Synonyms:	MBX-8025; RWJ-800025
Iupac Name:	2-[4-[(2''R'')-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid
C:	21
H:	23
F:	3
O:	5
S:	1
Smiles:	CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C
Stdinchi:	1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1
Stdinchikey:	JWHYSEDOYMYMNM-QGZVFWFLSA-N

Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis. It is used as the lysine dihydrate salt. It is a PPARδ receptor agonist.^[2] ^[3] The compound was licensed from Janssen Pharmaceutica NV.^[4]

Seladelpar was approved for medical use in the United States in August 2024.^[5]

Medical uses

Seladelpar is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.

Notes and References

https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217899s000lbl.pdf
Billin AN . PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home . Expert Opinion on Investigational Drugs . 17 . 10 . 1465–1471 . October 2008 . 18808307 . 10.1517/13543784.17.10.1465 . 86564263 .
Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK . MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin . The Journal of Clinical Endocrinology and Metabolism . 96 . 9 . 2889–2897 . September 2011 . 21752880 . 10.1210/jc.2011-1061 . free .
Web site: Targeting Mixed Dyslipidemia and Metabolic Syndrome . Metabolex, Inc. . 2005 . https://web.archive.org/web/20061017202546/http://www.metabolex.com/MBX-8025.html. dead. 17 October 2006.
Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA . Gilead . Business Wire . 14 August 2024 . 15 August 2024.